{"address1": "117 Kendrick Street", "address2": "Suite 500", "city": "Needham", "state": "MA", "zip": "02494", "country": "United States", "phone": "781 292 4200", "website": "https://www.verastem.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.", "fullTimeEmployees": 78, "companyOfficers": [{"maxAge": 1, "name": "Mr. Daniel W. Paterson", "age": 63, "title": "President, CEO & Director", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 897590, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel  Calkins", "age": 36, "title": "Chief Financial Officer", "yearBorn": 1988, "fiscalYear": 2023, "totalPay": 401833, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert A. Weinberg Ph.D.", "title": "Co-Founder & Chair of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michelle  Detwiler M.D., Ph.D.", "age": 48, "title": "Co-Founder", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew E. Ros", "age": 57, "title": "Chief Operating Officer", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jonathan  Pachter Ph.D.", "age": 66, "title": "Chief Scientific Officer", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 238176, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Cathy  Carew", "title": "Chief Organizational Effectiveness Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nate  Sanburn", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Crowther", "title": "Chief Commercial & Strategy Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Colleen  Mockbee", "title": "Global Head of Regulatory Affairs & Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 6, "shareHolderRightsRisk": 7, "overallRisk": 7, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 6.03, "open": 6.0, "dayLow": 5.815, "dayHigh": 6.3294, "regularMarketPreviousClose": 6.03, "regularMarketOpen": 6.0, "regularMarketDayLow": 5.815, "regularMarketDayHigh": 6.3294, "payoutRatio": 0.0, "beta": 0.601, "forwardPE": -2.3003953, "volume": 1612043, "regularMarketVolume": 1612043, "averageVolume": 951776, "averageVolume10days": 815480, "averageDailyVolume10Day": 815480, "bid": 5.79, "ask": 5.84, "bidSize": 1, "askSize": 1, "marketCap": 299652608, "fiftyTwoWeekLow": 2.1, "fiftyTwoWeekHigh": 13.52, "priceToSalesTrailing12Months": 29.965261, "fiftyDayAverage": 6.1548, "twoHundredDayAverage": 4.1669, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 253088624, "profitMargins": 0.0, "floatShares": 34121784, "sharesOutstanding": 51486700, "sharesShort": 7321486, "sharesShortPriorMonth": 5582900, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.16350001, "heldPercentInsiders": 0.0101, "heldPercentInstitutions": 0.65946996, "shortRatio": 8.68, "shortPercentOfFloat": 0.16399999, "impliedSharesOutstanding": 52852900, "bookValue": -0.645, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -130637000, "trailingEps": -3.66, "forwardEps": -2.53, "lastSplitFactor": "1:12", "lastSplitDate": 1685577600, "enterpriseToRevenue": 25.309, "enterpriseToEbitda": -2.202, "52WeekChange": -0.5141903, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 5.82, "targetHighPrice": 20.0, "targetLowPrice": 9.0, "targetMeanPrice": 12.85714, "targetMedianPrice": 14.0, "recommendationMean": 1.25, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 88818000, "totalCashPerShare": 1.725, "ebitda": -114930000, "totalDebt": 42254000, "quickRatio": 2.874, "currentRatio": 3.066, "totalRevenue": 10000000, "revenuePerShare": 0.28, "returnOnAssets": -0.57191, "returnOnEquity": -5.26338, "grossProfits": 10000000, "freeCashflow": -62409752, "operatingCashflow": -104771000, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -11.495601, "financialCurrency": "USD", "symbol": "VSTM", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": -3.4825876, "regularMarketPrice": 5.82, "marketState": "PRE", "shortName": "Verastem, Inc.", "longName": "Verastem, Inc.", "corporateActions": [], "preMarketTime": 1743596562, "regularMarketTime": 1743537600, "exchange": "NCM", "messageBoardId": "finmb_115881768", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "preMarketChange": 0.2956996, "preMarketChangePercent": 5.080749, "preMarketPrice": 6.1157, "regularMarketChange": -0.21000004, "regularMarketDayRange": "5.815 - 6.3294", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 951776, "fiftyTwoWeekLowChange": 3.7200003, "fiftyTwoWeekLowChangePercent": 1.7714288, "fiftyTwoWeekRange": "2.1 - 13.52", "fiftyTwoWeekHighChange": -7.7000003, "fiftyTwoWeekHighChangePercent": -0.5695266, "fiftyTwoWeekChangePercent": -51.419033, "earningsTimestamp": 1742500860, "earningsTimestampStart": 1746615540, "earningsTimestampEnd": 1747051200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.66, "epsForward": -2.53, "epsCurrentYear": -2.35, "priceEpsCurrentYear": -2.4765959, "fiftyDayAverageChange": -0.33479977, "fiftyDayAverageChangePercent": -0.054396532, "twoHundredDayAverageChange": 1.6531, "twoHundredDayAverageChangePercent": 0.39672178, "priceToBook": -9.023256, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1327674600000, "displayName": "Verastem", "trailingPegRatio": null}